Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Dramatic Analyst Forecast Downgrade

Stock Track11-13

Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a shadow over the biotech firm's future prospects, leading to a sell-off among investors.

According to the latest analyst consensus, CytomX Therapeutics is now expected to generate revenues of just US$31 million in 2026, a substantial reduction from the previous estimate of US$50 million. This revision implies a painful 73% decline in sales compared to the last year of performance. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of US$0.40 per share in 2026, compared to the earlier expectation of US$0.27 per share loss.

The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. Analysts project an annualized revenue decline of 65% by the end of 2026 for the company, a stark contrast to its 22% annual growth over the past five years. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106739565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106739565","market":"us","top_or_hot":-1,"title":"Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Dramatic Analyst Forecast Downgrade","media":"Stock Track","content":"<p>Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a shadow over the biotech firm's future prospects, leading to a sell-off among investors.</p>\n\n<p>According to the latest analyst consensus, CytomX Therapeutics is now expected to generate revenues of just US$31 million in 2026, a substantial reduction from the previous estimate of US$50 million. This revision implies a painful 73% decline in sales compared to the last year of performance. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of US$0.40 per share in 2026, compared to the earlier expectation of US$0.27 per share loss.</p>\n\n<p>The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. Analysts project an annualized revenue decline of 65% by the end of 2026 for the company, a stark contrast to its 22% annual growth over the past five years. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Dramatic Analyst Forecast Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Dramatic Analyst Forecast Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a shadow over the biotech firm's future prospects, leading to a sell-off among investors.</p>\n\n<p>According to the latest analyst consensus, CytomX Therapeutics is now expected to generate revenues of just US$31 million in 2026, a substantial reduction from the previous estimate of US$50 million. This revision implies a painful 73% decline in sales compared to the last year of performance. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of US$0.40 per share in 2026, compared to the earlier expectation of US$0.27 per share loss.</p>\n\n<p>The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. Analysts project an annualized revenue decline of 65% by the end of 2026 for the company, a stark contrast to its 22% annual growth over the past five years. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTMX","symbol_name":"CytomX","start_time":0,"source_url":"","article_id":"1106739565","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106739565","pubTimestamp":1763040043,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTMX":"CytomX"},"translate_title":"个股追踪|分析师大幅下调预期后CytomX Therapeutics盘前暴跌5.20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1},"content_text":"Shares of CytomX Therapeutics (NASDAQ:CTMX) tumbled 5.20% in pre-market trading on Thursday after analysts significantly downgraded their forecasts for the company. The dramatic revision has cast a shadow over the biotech firm's future prospects, leading to a sell-off among investors.\nAccording to the latest analyst consensus, CytomX Therapeutics is now expected to generate revenues of just US$31 million in 2026, a substantial reduction from the previous estimate of US$50 million. This revision implies a painful 73% decline in sales compared to the last year of performance. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of US$0.40 per share in 2026, compared to the earlier expectation of US$0.27 per share loss.\nThe downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. Analysts project an annualized revenue decline of 65% by the end of 2026 for the company, a stark contrast to its 22% annual growth over the past five years. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106739565","isCrawlerRequest":true}